This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Historx, Inc., Radiation Therapy Oncology Group of the American College of Radiology. Active years: 2013.
Company Filing History:
1 out of 17 
1 out of 1 Years Active: 2013
Title: The Innovations of Donald Waldron
Introduction
Donald Waldron is an accomplished inventor based in Fairfield, CT (US). He has made significant contributions to the field of molecular biology, particularly in understanding the clinical outcomes of patients with glioblastoma multiforme (GBM) treated with gefitinib. His work has implications for personalized medicine and cancer treatment strategies.
Latest Patents
Waldron holds a patent titled "Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib." This patent highlights the differences in significant biomarkers for gefitinib-treated GBM patients compared to those who were not treated with gefitinib. Notably, it was found that patients with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, non-gefitinib-treated patients exhibited different adverse clinical outcomes based on their biomarker levels, emphasizing the treatment-dependency of these markers.
Career Highlights
Throughout his career, Waldron has worked with notable organizations such as Historx, Inc. and the Radiation Therapy Oncology Group of the American College of Radiology. His expertise in molecular markers and their correlation with treatment outcomes has positioned him as a key figure in cancer research.
Collaborations
Waldron has collaborated with esteemed colleagues, including Arnab Chakravarti and Robert Pinard. These partnerships have furthered research in the field and contributed to advancements in understanding GBM treatment.
Conclusion
Donald Waldron's innovative work in the realm of molecular biology and cancer treatment exemplifies the importance of research in improving clinical outcomes for patients. His contributions continue to influence the field and pave the way for future advancements in personalized medicine.